ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.

Sepp Braun, G. Schlimok, Isabella Heumos, +4

PubMed

Breast OncologyImmunologyPathologyCancer BiologyTumor Biology +14

Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with <i>de novo</i> AML

Jürgen Krauter, Wolfgang Peter, Ulrich Pascheberg, +10

British Journal of Haematology

Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients

Ralf Schulze, Monika Schulze, A. Wischnik, +5

Bone Marrow Transplantation

Breast OncologyTransplantationMarrow TransplantationMedicineStem Cell Mobilization +9

Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse

Tim Pfeiffer, Michael Schleuning, Jiří Mayer, +17

Haematologica

Shift from cytoplasmic to nuclear maspin expression correlates with shorter overall survival in node-negative colorectal cancer

Bruno Märkl, H Arnholdt, Hendrik Jähnig, +7

Human Pathology

Tumor BiologyNuclear Maspin ExpressionMedicinePathologyColorectal Cancer +7

Mitoxantrone, Cytosine Arabinoside, and VP-16 in 36 Patients with Relapsed and Refractory Acute Myeloid Leukemia

Hartmut Link, M. Freund, H. Diedrich, +9

Hämatologie und Bluttransfusion

Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematology +6

Association between structural and numerical chromosomal aberrations in acute myeloblastic leukemia: a study by RT-PCR and FISH in 447 patients with de-novo AML

J Krauter, Arnold Ganser, Lothar Bergmann, +8

Annals of Hematology

Hematological MalignancyChromatinDe-novo AmlCytogeneticsAcute Myeloblastic Leukemia +8

Treatment results of the thioether lipid ilmofosine in patients with malignant tumours

M. Winkelmann, K Ebeling, G Strohmeyer, +7

Journal of Cancer Research and Clinical Oncology

MedicineMalignant TumoursPharmacologyPathologyTreatment Results +2

Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-Trial

Andreas Schalhorn, F. W. Ludwig, D. Quietzsch, +8

Journal of Clinical Oncology

PharmacotherapyPre-clinical PharmacologyFolfiri Vs IroxOncologyGastrointestinal Oncology +18